Eric D. Shaff

Eric D. Shaff discloses dealings in Seres Therapeutics, Inc. to SEC (Form 4). The record holds 14 filings, for trades running from 5 July 2022 to 17 August 2026.

Sales make up the whole of the open-market record (1 sale, €1,033). Other entries cover 1 share grant and 12 option exercises. 2026 to date brings no purchases and 1 sale.

On 18 August 2026 came the latest disclosure, an option exercise in Seres Therapeutics, Inc. Filings reach the SEC (Form 4) feed a median of 3 days after the trade. For comparison, the SEC allows two business days to file a Form 4. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.